Shenzhen and Hong Kong work together to draw a New blueprint for cross-border healthcare - Dr Kitty So, Director of Hong Kong Hospital Authority and Hong Kong Island East Hospital Cluster, visited She
Under the guidance of Chairman Shi Yuan, the visitor group visited the digital wisdom exhibition hall, GMP R & D production laboratory and quality management laboratory of Shenzhen Cell Valley, and learned about the latest research results and laboratory layout in the field of cell therapy in Shenzhen Cell Valley.
In the following symposium, Chairman Shi Yuanyuan comprehensively introduced the strategic planning, core technology and R&D team of Shenzhen Cell Valley. Chairman Yuan stressed that according to the strategic development plan, Shenzhen Cell Valley has set up a subsidiary in Hong Kong - Cell Valley (Hong Kong) Holding Company, which marks that Cell Valley has made significant progress in strategic deployment this year. In addition, recently, the R&D team of Shenzhen Cell Valley cooperated with the medical team of the city's public first-class hospital, and published a clinical cure case on the first application of retroviral vector technology to prepare CAR T cells targeting BCMA for the treatment of advanced multiple myeloma in an internationally renowned journal. This case reveals that the clinical-grade cell products produced by Shenzhen Cell Valley have high yield, low cost and efficient transfection and in vivo expansion capabilities, and it is because of these significant advantages that they have won high recognition from doctors.
Dr. So expressed her high recognition of the strategic development plan, core technologies and clinical application cases formulated by Shenzhen Cell Valley, and introduced that the Hong Kong East Hospital Cluster is managed by the Hospital Authority of Hong Kong, which implements a unified administrative and service management system, establishes a unified clinical practice and is in line with international standards. The network covers the Eastern District, Wan Chai and outlying Islands, serving a population of about 800,000, accounting for 12% of Hong Kong's population. Among them, Pamela Youde Nethersole Eastern Hospital is one of the hospitals in the Hong Kong East Hospital Cluster and mainly performs the functions of a district emergency hospital providing comprehensive specialist services. Dr. Su Jieying pointed out that the medical field is facing unprecedented challenges in view of the aging population trend and the continuous increase in the number of patients with chronic diseases. She expects that through in-depth cooperation with Shenzhen Cell Valley in scientific research projects and clinical applications, Hong Kong East Hospital Network can introduce more advanced cell therapy technology, so as to provide patients with more accurate and effective treatment programs.
At the end of the symposium, the two sides reached a consensus that they would jointly promote the development of cell therapy in Shenzhen and Hong Kong by relying on the resource sharing platform between Hong Kong and Hong Kong, so as to provide better services to residents of the two places.
